Standard-dose therapy for multiple myeloma: The Southwest Oncology Group experience (Q34326498)

1 August 2017

1 reference

title

Standard-dose therapy for multiple myeloma: The Southwest Oncology Group experience (English)

1 reference

1 August 2017

1 reference

Crowley J

1

1 reference

1 August 2017

Jacobson J

series ordinal

2

1 reference

1 August 2017

Alexanian R

series ordinal

3

1 reference

1 August 2017

publication date

1 July 2001

1 reference

1 August 2017

published in

Seminars in Hematology

1 reference

1 August 2017

volume

38

1 reference

1 August 2017

issue

3

1 reference

1 August 2017

page(s)

203-208

1 reference

Prognostic factors in multiple myeloma

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990011-3

7 January 2021

Combination therapy for multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990011-3

7 January 2021

Chemoimmunotherapy for multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990011-3

7 January 2021

Chemotherapy for multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990011-3

7 January 2021

Whither interferon for myeloma and other hematologic malignancies?

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990011-3

7 January 2021

Effective treatment of advanced multiple myeloma refractory to alkylating agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990011-3

7 January 2021

Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990011-3

7 January 2021

A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990011-3

7 January 2021

Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990011-3

7 January 2021

Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990011-3

7 January 2021

Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990011-3

7 January 2021

Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990011-3

7 January 2021

10.1016/S0037-1963(01)90011-3

Identifiers

DOI

1 reference

1 August 2017

1 reference